Kodiak Sciences (K27) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

K27 Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Kodiak

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

K27 Stock 12 Month Forecast

Average Price Target

€54.24

▲(55.87% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is €54.24 with a high forecast of €57.28 and a low forecast of €50.34. The average price target represents a 55.87% change from the last price of €34.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","31":"€31","58":"€58","17.5":"€17.5","44.5":"€44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.28008132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.24250125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€54.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.33704116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€50.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17.5,31,44.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.64,38.22769856307692,39.81539712615385,41.40309568923077,42.990794252307694,44.578492815384614,46.16619137846154,47.75388994153846,49.34158850461539,50.92928706769231,52.516985630769234,54.104684193846154,55.69238275692308,{"y":57.28008132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.64,37.994038557692306,39.34807711538461,40.702115673076925,42.05615423076923,43.410192788461536,44.76423134615384,46.118269903846155,47.47230846153846,48.82634701923077,50.18038557692307,51.53442413461538,52.888462692307684,{"y":54.24250125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.64,37.69361855076923,38.74723710153846,39.80085565230769,40.854474203076926,41.908092753846155,42.961711304615385,44.015329855384614,45.068948406153844,46.12256695692308,47.17618550769231,48.22980405846154,49.28342260923077,{"y":50.33704116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.635,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.64,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€57.28

Average Price Target€54.24

Lowest Price Target€50.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Dolezal

LifeSci Capital

€56.41

Buy

62.10%

Upside

Reiterated

08/06/26

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

Anupam Rama

J.P. Morgan

€48.6→€57.28

Buy

64.60%

Upside

Assigned

08/03/26

Kodiak Sciences price target raised to $66 from $56 at JPMorganKodiak Sciences price target raised to $66 from $56 at JPMorgan

Matthew Caufield

H.C. Wainwright

€50.34

Buy

44.65%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Daniil Gataulin

Chardan Capital

€52.94

Buy

52.13%

Upside

Upgraded

05/11/26

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), BioNTech SE (NASDAQ: BNTX) and Kodiak Sciences (NASDAQ: KOD)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/27/26

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Kodiak Sciences (KOD)

Michael Yee

UBS

€43.39→€69.43

Buy

99.51%

Upside

Reiterated

03/27/26

Kodiak Sciences price target raised to $80 from $50 at UBSKodiak Sciences price target raised to $80 from $50 at UBS

Maury Raycroft

Jefferies

€33.85→€48.6

Buy

39.66%

Upside

Assigned

03/26/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Kodiak Sciences (NASDAQ: KOD)

Gena Wang

Barclays

€14.75

Hold

-57.60%

Downside

Reiterated

11/17/25

Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Dolezal

LifeSci Capital

€56.41

Buy

62.10%

Upside

Reiterated

08/06/26

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

Anupam Rama

J.P. Morgan

€48.6→€57.28

Buy

64.60%

Upside

Assigned

08/03/26

Kodiak Sciences price target raised to $66 from $56 at JPMorganKodiak Sciences price target raised to $66 from $56 at JPMorgan

Matthew Caufield

H.C. Wainwright

€50.34

Buy

44.65%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Daniil Gataulin

Chardan Capital

€52.94

Buy

52.13%

Upside

Upgraded

05/11/26

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), BioNTech SE (NASDAQ: BNTX) and Kodiak Sciences (NASDAQ: KOD)

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/27/26

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Kodiak Sciences (KOD)

Michael Yee

UBS

€43.39→€69.43

Buy

99.51%

Upside

Reiterated

03/27/26

Kodiak Sciences price target raised to $80 from $50 at UBSKodiak Sciences price target raised to $80 from $50 at UBS

Maury Raycroft

Jefferies

€33.85→€48.6

Buy

39.66%

Upside

Assigned

03/26/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Kodiak Sciences (NASDAQ: KOD)

Gena Wang

Barclays

€14.75

Hold

-57.60%

Downside

Reiterated

11/17/25

Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kodiak Sciences

3 Months

Anupam RamaJ.P. Morgan

Success Rate

6/7 ratings generated profit

Average Return

+31.47%

Copying Anupam Rama's trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +31.47% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

7/7 ratings generated profit

Average Return

+61.07%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +61.07% per trade.

2 Years

Matthew CaufieldH.C. Wainwright

Success Rate

6/6 ratings generated profit

Average Return

+55.05%

Copying Matthew Caufield's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +55.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

K27 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, K27 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. K27 average Analyst price target in the past 3 months is 54.24.

Each month's total comprises the sum of three months' worth of ratings.

K27 Financial Forecast

K27 Earnings Forecast

Next quarter’s earnings estimate for K27 is -€0.83 with a range of -€0.86 to -€0.80. The previous quarter’s EPS was ―. K27 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year K27 has Performed in-line its overall industry.

No data currently available

K27 Sales Forecast

Next quarter’s sales forecast for K27 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were ―. K27 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year K27 has Performed in-line its overall industry.

K27 Stock Forecast FAQ

What is DE:K27’s average 12-month price target, according to analysts?

Based on analyst ratings, Kodiak Sciences Inc’s 12-month average price target is 54.24.

What is DE:K27’s upside potential, based on the analysts’ average price target?

Kodiak Sciences Inc has 55.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Kodiak Sciences Inc a Buy, Sell or Hold?

Kodiak Sciences Inc has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kodiak Sciences Inc’s share price target?

The average share price target for Kodiak Sciences Inc is 54.24. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €57.28 ,and the lowest forecast is €50.34. The average share price target represents 55.87% Increase from the current price of €34.8.

What do analysts say about Kodiak Sciences Inc?

Kodiak Sciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Kodiak Sciences Inc?

To buy shares of DE:K27, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Kodiak Sciences (K27) Stock Forecast & Price Target

K27 Analyst Ratings

K27 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kodiak Sciences

K27 Analyst Recommendation Trends

K27 Financial Forecast

K27 Earnings Forecast

K27 Sales Forecast

K27 Stock Forecast FAQ

Detailed List of Analyst Forecasts